Discover
Talzenna (talazoparib) / PfizerA Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (clinicaltrials.gov) - Jan 24, 2020 - P3; N=429; Recruiting; Sponsor: BioMarin Pharmaceutical
Kadcyla (ado-trastuzumab emtansine) / RocheSwiss Regulator grants additional approval for Roche’s antibody-drug Kadcyla (Reuters) - Jan 24, 2020 - "ROCHE’S KADCYLA APPROVED FOR A NEW INDICATION IN EARLY HER2-POSITIVE BREAST CANCER IN SWITZERLAND...ADDITIONAL APPROVAL OF KADCYLA IS BASED ON THE PHASE III KATHERINE STUDY, IN WHICH PATIENTS WITH AN EARLY FORM OF HER2-POSITIVE BREAST CANCER WHO WERE TREATED WITH KADCYLA HAD A 50% REDUCED RISK OF RELAPSE OR DEATH COMPARED TO STANDARD THERAPY."
Tecentriq (atezolizumab) / RocheIMpassion131: A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Jan 22, 2020 - P3; N=600; Recruiting; Sponsor: Hoffmann-La Roche; Active, not recruiting --> Recruiting
Ibrance (palbociclib) / PfizerIbrance pricing: Wholesale acquisition cost of $10,963/month (Cowen & Co) - Jan 24, 2020 - A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 646; REPORT TITLE: - “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020
Kisqali (ribociclib) / NovartisKisqali pricing: $10,950/600mg for 28-days, $8,760/400mg dose and $4,380/200mg dose (Cowen & Co) - Jan 24, 2020 - A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 548; REPORT TITLE: - “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020
